Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Latar belakang. Kemajuan terapi reperfusi pada pasien infark miokard akut menimbulkan satu fenomena yang turut berperan dalam prognosis pasien, yaitu fenomena no reflow atau obstruksi mikrovaskular. Mekanisme OMV diduga memiliki 4 komponen patogenik utama yaitu embolisasi distal aterotrombotik, cedera reperfusi, cedera iskemia, dan kerentanan individu. Hiperglikemia akut diketahui berhubungan dengan OMV pada pasien IMA, namun peran hiperglikemia kronik masih kontroversial. Hiperglikemia berperan dalam komponen kerentanan individu, serta mempengaruhi peningkatan faktor inflamasi yang berperan dalam komponen cedera reperfusi. Kedua faktor ini yaitu hiperglikemia kronik yang digambarkan HbA1C dan inflamasi yang digambarkan hsCRP belum pernah diteliti secara bersamaan dalam menilai OMV dengan satu metode. Penelitian ini akan meneliti hubungan antara HbA1C dan hsCRP dengan OMV yang dinilai menggunakan indeks resistensi mikrovaskular, suatu metode terbaru dalam menilai OMV dengan akurat pada fase awal dan memiliki nilai prognostik yang signifikan. Metode. Sebanyak 55 pasien IMA-EST yang menjalani IKPP dipilih secara konsekutif sejak Januari-Juni 2014. HbA1C dan hsCRP diambil saat masuk UGD, penilaian IMR diambil segera setelah tindakan IKPP. Perhitungan statistik menggunakan SPSS 17. Hasil. Dari 55 pasien didapatkan proporsi laki-laki sebesar 93%, dengan rerata umur 51,91 ± 8,87 tahun. Faktor resiko penyakit jantung koroner terbanyak adalah merokok yaitu 69%. Semua pasien menjalani tindakan IKPP dengan waktu iskemia 489,45±169,95 menit dan waktu perfusi 124,91±76,49 menit. Nilai rerata IRM 53,22±41,11 dengan nilai rerata HbA1C 6,46±1,22 %, dan rerata hsCRP 4,98±3,39 mg/dL. Dari analisis bivariat didapatkan HbA1C tidak berhubungan dengan IRM (r=0,22,p=0,10), dan hsCRP juga tidak berhubungan dengan IRM (r=0,24,p=0,08). Setelah disesuaikan dengan variabel perancu pada analisis multivariat, didapatkan hubungan signifikan antara HbA1C dengan IRM (p=0,03) namun hsCRP tidak berhubungan dengan IRM (p=0,31). Kesimpulan. Kadar HbA1C saat admisi berhubungan dengan IRM pada pasien IMA-EST yang menjalani IKPP dan hsCRP saat admisi tidak berhubungan dengan IRM pasien IMA-EST yang menjalani IKPP. ......Background: Advances in reperfusion therapy for acute myocardial infarction led to a phenomenon of distal no reflow or myocardial obstruction (MVO), which associated with worse outcome and prognosis. The potential mechanism of MVO had four major pathogenic components: distal atherotrombotic embolization, reperfusion injury, ischemic injury, and individual susceptibility. Association between acute hyperglycemia and MVO in acute myocardial infarction has been found, but the role of chronic hyperglycemia remained controversial. Hyperglycemia affected individual susceptibility to microcirculatory injury, and also induced systemic inflammation which had a role in reperfusion injury. Association of both these factors--chronic hyperglycemia, determined by Hemoglobin A1C, and inflammation factor, measured by high sensitivity C-Reactive Protein-- with MVO had never been studied simultaneously. This cross-sectional study will determine the association between HbA1C and hsCRP with MVO assessed with index of microvascular resistance, an invasive novel method to assess MVO in acute phase and had significant prognostic factor. Methods: 55 patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention were taken consecutively from January to June 2014. Blood samples for HbA1C and hsCRP were taken before the procedure. IMR was taken immediately after the primary percutaneous coronary intervention procedure. Statistical calculation used SPSS 17. Results: From 55 patients included in the study, there were 93% men, with mean age of 51.91 ± 8.87 years. The most common risk factors for coronary heart disease was smoking (69%). All patients underwent primary percutaneous coronary intervention with mean onset to balloon time was 489.45 ± 169.95 minutes and mean door to balloon time was 124.91 ± 76.49 minutes. Mean IMR was 53.22 ± 41.11, with mean HbA1c was 6.46 ± 1.22% and mean hsCRP was 4.98 ± 3.39 mg/dL . From bivariate analysis, there was no association between HbA1C and IMR (r=0,22, p = 0,10), and between hsCRP and IMR (r = 0,24 , p=0,08). In multivariate analysis , there was relationship between HbA1C with IRM ( p = 0,03) and hsCRP were also not associated with IRM ( p = 0,31 ). Conclusions. There was association between hemoglobin A1C levels on admission with IMR and no association between hsCRP levels on admission with IMR, in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.

Abstrak :
Latar Belakang: Statin (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) melalui efek pleiotrofiknya telah terbukti menurunkan angka kejadian kardiovaskular mayor (KKM) setelah intervensi perkutan pada pasien angina pektoris stabil maupun pasien sindroma koroner akut. Namun masih banyak perdebatan mengenai manfaat statin segera sebelum dilakukan intervensi perkutan primer (IKPP) pada pasien IMA-EST. Tujuan: Untuk mengetahui pengaruh pemberian terapi akut atorvastatin dosis tinggi (80 mg) dan plasebo sebelum IKPP terhadap perfusi mikrovaskular pada pasien IMA-EST yang dinilai dengan teknik IRM (indeks resistensi mikrovaskular). IRM merupakan pemeriksaan mikrovaskular yang spesifik dan bersifat kuantitatif, dapat memberikan nilai prognostik dan prediktor perbaikan fungsi ventrikel kiri setelah dilakukannya IKPP. Metode: Penelitian ini merupakan studi eksperimental acak yang tersamar ganda. Diberikan atorvastatin dosis 80 mg atau plasebo. Sampel diambil secara consecutive dari populasi terjangkau IMA-EST yang menjalani IKPP dan memenuhi kriteria inklusi dan eksklusi. Reperfusi miokardium dinilai dengan parameter IRM dengan menggunakan kawat dengan sensor tekanan dan suhu setelah IKPP selesai dilakukan. Hasil Penelitian: Terdapat 66 sampel yang terbagi dalam 2 kelompok yakni 32 orang mendapatkan atorvastatin 80 mg dan 34 orang mendapatkan plasebo. Tidak didapatkan perbedaan yang signifikan pada kelompok yang mendapatkan atorvastatin 80 mg dan plasebo dalam hal parameter fractional flow reserve (FFR) (0.94 vs. 0.96, p = 0.39), coronary flow reserve (CFR) (1.1 vs. 1.2, p = 0.09) dan IRM (41.54 [12.8-198.2] vs. 41.60 [10.4 ? 200.3], p = 0.61). Kesimpulan: Pemberian terapi atorvastatin dosis tinggi 80 mg sebelum tindakan IKPP pada pasien IMA-EST tidak memberikan pengaruh terhadap perfusi mikrovaskular yang dinilai dengan parameter IMR. ......Background: Statin (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), given before percutaneous coronary intervention (PCI) was proven to reduce Major Cardiovascular Events (MACE) in patient with stable angina as well as acute coronary syndromes through its pleiotropic effect. Nevertheless, the debate regarding statin administration before primary PCI (PPCI) in STEMI patients is still on the rise. Objective: To establish therapeutic effect of high dose atorvastatin (80 mg) and placebo before primary PCI on microvascular perfusion in STEMI patient using index of microcirculatory resistance (IMR). IMR are specific and quantitative assessment of coronary microvascular dysfunction, reliable on-site predictors of short-term myocardial viability and left ventricle functional recovery of patients undergoing primary PCI for STEMI. Methods: This study is a double blind randomized controlled trial. A high loading dose of atorvastatin (80 mg) or placebo was administered before PPCI. Samples were taken from the population of STEMI patients which underwent PPCI and meet the inclusion and exclusion criteria. The primary end point of this study is IMR. After successful primary percutaneous coronary intervention, IMR was measured using a pressure-temperature sensor-tipped coronary guidewire. Result: Total of 66 patients was divided into 2 groups, atorvastatin group (32 patients) and placebo group (34 patients). There were no significant differences between both groups in regard of fractional flow reserve (FFR) (0.94 vs. 0.96, p = 0.39), coronary flow reserve (CFR) (1.1 vs. 1.2, p = 0.09) and also IMR (41.54 [12.8-198.2] vs. 41.60 [10.4 ? 200.3], p = 0.61). Conclusion: Administration of high loading dose of atorvastatin (80 mg) before primary PCI in STEMI patients didn?t have effect on microvascular perfusion measured by index of microcirculatory resistance.